Skip header and navigation

Refine By

5 records – page 1 of 1.

Aberrant circulating levels of purinergic signaling markers are associated with several key aspects of peripheral atherosclerosis and thrombosis.

https://arctichealth.org/en/permalink/ahliterature263533
Source
Circ Res. 2015 Mar 27;116(7):1206-15
Publication Type
Article
Date
Mar-27-2015
Author
Juho Jalkanen
Gennady G Yegutkin
Maija Hollmén
Kristiina Aalto
Tuomas Kiviniemi
Veikko Salomaa
Sirpa Jalkanen
Harri Hakovirta
Source
Circ Res. 2015 Mar 27;116(7):1206-15
Date
Mar-27-2015
Language
English
Publication Type
Article
Keywords
5'-Nucleotidase - blood
Adenosine Diphosphate - blood
Adenosine Triphosphate - blood
Adult
Age Factors
Aged
Aged, 80 and over
Alkaline Phosphatase - blood
Angiotensin-Converting Enzyme Inhibitors - therapeutic use
Anoxia - blood
Antigens, CD - blood
Apyrase - blood
Artifacts
Atherosclerosis - blood - epidemiology
Biological Markers
Chronic Disease
Comorbidity
Disease Progression
Drug Utilization
Female
Finland - epidemiology
GPI-Linked Proteins - blood
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
Hypertension - blood - drug therapy - epidemiology
Male
Middle Aged
Models, Cardiovascular
Peripheral Arterial Disease - blood - epidemiology
Purinergic P2Y Receptor Antagonists - therapeutic use
Risk factors
Second Messenger Systems
Smoking - adverse effects - blood - epidemiology
Thrombophilia - blood - epidemiology - etiology
Abstract
Purinergic signaling plays an important role in inflammation and vascular integrity, but little is known about purinergic mechanisms during the pathogenesis of atherosclerosis in humans.
The objective of this study is to study markers of purinergic signaling in a cohort of patients with peripheral artery disease.
Plasma ATP and ADP levels and serum nucleoside triphosphate diphosphohydrolase-1 (NTPDase1/CD39) and ecto-5'-nucleotidase/CD73 activities were measured in 226 patients with stable peripheral artery disease admitted for nonurgent invasive imaging and treatment. The major findings were that ATP, ADP, and CD73 values were higher in atherosclerotic patients than in controls without clinically evident peripheral artery disease (P
PubMed ID
25645301 View in PubMed
Less detail

Both hypertensive men and women are inadequately treated in Finnish general practice.

https://arctichealth.org/en/permalink/ahliterature137748
Source
J Am Soc Hypertens. 2011 Jan-Feb;5(1):31-8
Publication Type
Article
Author
Juha Varis
Heljä Savola
Risto Vesalainen
Ilkka Kantola
Author Affiliation
Department of Medicine, Turku University Hospital, Turku, Finland. juha.varis@tyks.fi
Source
J Am Soc Hypertens. 2011 Jan-Feb;5(1):31-8
Language
English
Publication Type
Article
Keywords
Adult
Aged
Angiotensin Receptor Antagonists - administration & dosage
Angiotensin-Converting Enzyme Inhibitors - administration & dosage
Antihypertensive Agents - administration & dosage
Comorbidity
Cross-Sectional Studies
Drug Therapy, Combination
Female
Finland - epidemiology
General practice
Humans
Hypertension - blood - drug therapy - epidemiology
Male
Middle Aged
Physician's Practice Patterns
Smoking - epidemiology
Abstract
A general comprehension is that men are treated poorer than women. This study was planned to assess the Finnish hypertensive care with interests in possible hypertensive and cardiovascular control differences between men and women. A cross-sectional study was carried out by nationwide questionnaire survey of 714 consecutive drug-treated hypertensive patients having visited general practice during autumn 2006. Mean (SD) blood pressure (BP) of the women was 148.3 (21.1)/86.8 (11.7) mm Hg and of men 146.5 (19.5)/89.0 (11.8). Women had significantly lower diastolic BP (P = .016). The mean LDL cholesterol of women was 2.94 (0.91) mmol/L and of men 2.95 (0.94) mmol/L (P = .94). The blood pressure target
PubMed ID
21251897 View in PubMed
Less detail

N-terminal brain natriuretic peptide predicted cardiovascular events stronger than high-sensitivity C-reactive protein in hypertension: a LIFE substudy.

https://arctichealth.org/en/permalink/ahliterature168101
Source
J Hypertens. 2006 Aug;24(8):1531-9
Publication Type
Article
Date
Aug-2006
Author
Michael H Olsen
Kristian Wachtell
Olav W Nielsen
Christian Hall
Ragnhild Wergeland
Hans Ibsen
Sverre E Kjeldsen
Richard B Devereux
Björn Dahlöf
Per R Hildebrandt
Author Affiliation
Department of Internal Medicine, Glostrup University Hospital, Glostrup, Denmark. mho@dadlnet.dk
Source
J Hypertens. 2006 Aug;24(8):1531-9
Date
Aug-2006
Language
English
Publication Type
Article
Keywords
Aged
Aged, 80 and over
Albumins - metabolism
Antihypertensive Agents - therapeutic use
Atenolol - therapeutic use
Biological Markers - blood - urine
C-Reactive Protein - metabolism
Cardiovascular Diseases - epidemiology - metabolism
Confounding Factors (Epidemiology)
Creatinine - urine
Endpoint Determination
Female
Follow-Up Studies
Humans
Hypertension - blood - drug therapy - epidemiology - metabolism - urine
Hypertrophy, Left Ventricular - drug therapy - metabolism
Losartan - therapeutic use
Male
Middle Aged
Natriuretic Peptide, Brain - blood
Peptide Fragments - blood
Predictive value of tests
Proportional Hazards Models
ROC Curve
Risk factors
Scandinavia - epidemiology
Abstract
N-terminal pro-brain natriuretic peptide (Nt-proBNP) and high-sensitivity C-reactive protein (hsCRP) are cardiovascular risk markers in various populations, but are not well examined in hypertension. Therefore, we wanted to investigate whether high Nt-proBNP or hsCRP predicted the composite endpoint of cardiovascular death, non-fatal stroke or non-fatal myocardial infarction independently of traditional cardiovascular risk factors and the urine albumin: creatinine ratio (UACR), which is a well established cardiovascular risk factor in hypertension.
In 945 hypertensive patients from the LIFE study with electrocardiographic left ventricular (LV) hypertrophy, we measured traditional cardiovascular risk factors including electrocardiography, morning UACR, hsCRP by immunoturbidimetry assay and Nt-proBNP by immunoassay after 2 weeks of placebo treatment. During 55 months' follow-up 80 patients suffered a composite endpoint.
HsCRP as well as Nt-proBNP above the median values of 3.0 mg/l and 170 pg/ml, respectively, was associated with a higher incidence of composite endpoint (13.1 versus 3.8%, P
PubMed ID
16877955 View in PubMed
Less detail

The value of N-terminal pro-B-type natriuretic peptide in determining antihypertensive benefit: observations from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).

https://arctichealth.org/en/permalink/ahliterature105751
Source
Hypertension. 2014 Mar;63(3):507-13
Publication Type
Article
Date
Mar-2014
Author
Paul Welsh
Neil R Poulter
Choon L Chang
Peter S Sever
Naveed Sattar
Author Affiliation
BHF Glasgow Cardiovascular Research Centre, University of Glasgow, 126 University Pl, Glasgow G12 8TA, United Kingdom. Paul.Welsh@glasgow.ac.uk or Naveed.Sattar@glasgow.ac.uk.
Source
Hypertension. 2014 Mar;63(3):507-13
Date
Mar-2014
Language
English
Publication Type
Article
Keywords
Aged
Antihypertensive Agents - therapeutic use
Biological Markers - blood
Blood Pressure - drug effects
Female
Follow-Up Studies
Great Britain - epidemiology
Humans
Hypertension - blood - drug therapy - epidemiology
Male
Middle Aged
Natriuretic Peptide, Brain - blood
Odds Ratio
Peptide Fragments - blood
Prevalence
Prognosis
Protein Precursors
Retrospective Studies
Risk Assessment - methods
Risk factors
Scandinavia - epidemiology
Time Factors
Abstract
We investigated 3 hypotheses: (1) N-terminal pro-B-type natriuretic peptide (NT-proBNP) predicts cardiovascular disease events in patients with hypertension, (2) NT-proBNP is associated with blood pressure variability, and (3) NT-proBNP predicts benefit from antihypertensive regimens. The Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) randomized a subset of 6549 patients at risk with no history of coronary heart disease to either atenolol-based or amlodipine-based blood pressure-lowering treatment. During 5.5 years of follow-up, 485 cardiovascular disease cases accrued and were matched with 1367 controls. Baseline and 6-month in-trial NT-proBNP were measured. The results show that NT-proBNP improves cardiovascular disease risk prediction beyond established predictors, continuous net reclassification improvement of 22.3% (P
Notes
Comment In: Hypertension. 2014 Apr;63(4):e8724535010
PubMed ID
24324046 View in PubMed
Less detail